Why Tempus AI Stock Is Up Today — And What to Watch Before Next Week's Earnings

Core Insights - Tempus AI (TEM) shares increased following the launch of a new AI algorithm for identifying cancer patients responsive to platinum-based chemotherapy, with preliminary Q4 revenue reported at $367 million, an 83% year-over-year increase, and total contract value exceeding $1.1 billion [1] Group 1: Company Developments - Tempus AI introduced the Pan-Cancer HRD-RNA algorithm, which utilizes RNA analysis to identify Homologous Recombination Deficiency, offering a real-time view of tumor biology [1] - The algorithm has shown that patients with HRD-RNA positive metastatic pancreatic cancer have significantly lower mortality risk compared to those receiving non-platinum therapies [1] - The algorithm is currently available for research purposes, with clinical availability anticipated later in 2026 [1] Group 2: Financial Performance - Preliminary Q4 revenue for Tempus was reported at $367 million, marking an 83% increase year-over-year [1] - The total contract value for Tempus exceeded $1.1 billion, indicating strong demand for its services [1] Group 3: Market Sentiment - Analysts have set a consensus target price of $85.69 for Tempus, suggesting nearly 50% upside from current trading levels [1] - The stock has received 2 Strong Buy and 5 Buy ratings, reflecting confidence in Tempus's revenue growth and expanding AI-driven diagnostics platform [1] - Despite recent volatility, the stock remains down 18.54% over the past month, indicating potential market concerns ahead of the earnings report [1]